News & Updates

Fluvoxamine of little benefit in mild-to-moderate COVID-19

02 Jan 2024

The use of fluvoxamine for outpatient treatment of mild-to-moderate COVID-19 falls short of reducing the duration of symptoms, as shown in the ACTIV-6 study.

Fluvoxamine of little benefit in mild-to-moderate COVID-19

02 Jan 2024

Retinoblastoma treatment carries increased risk of neutropenia

30 Dec 2023

Neutropenia following intra-arterial chemotherapy occurs more frequently than previously reported among children with retinoblastoma, with topotecan possibly linked to a risk increase, according to a study.

Retinoblastoma treatment carries increased risk of neutropenia

30 Dec 2023

Statins protect against blood clots in people taking hormone therapy

30 Dec 2023 by

Statin therapy appears to mitigate the risk of venous thromboembolism associated with exogenous hormones, according to a study.

Statins protect against blood clots in people taking hormone therapy

30 Dec 2023

Is premedication with pronase advisable to patients undergoing endoscopy?

30 Dec 2023

Prior to upper gastrointestinal endoscopy, premedication with pronase helps achieve better mucosal visibility and reduce flushing frequency and volume, reports a study. However, this strategy does not appear to improve lesion detection rates.

Is premedication with pronase advisable to patients undergoing endoscopy?

30 Dec 2023

Telitacicept shows promise in systemic lupus erythematosus

30 Dec 2023

Telitacicept, a novel fusion protein that neutralizes signals of B lymphocyte stimulator and a proliferation-inducing ligand, is safe and helps improve the symptoms of systemic lupus erythematosus, as shown in a phase IIb study.

Telitacicept shows promise in systemic lupus erythematosus

30 Dec 2023

Brolucizumab noninferior to aflibercept for diabetic macular edema

29 Dec 2023

In the treatment of individuals with diabetic macular edema, brolucizumab yields similar visual outcomes as aflibercept, according to data from the phase III KINGFISHER trial.

Brolucizumab noninferior to aflibercept for diabetic macular edema

29 Dec 2023

$Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma$

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023 by

In the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), taking ibrutinib and venetoclax together prolongs survival without disease progression, according to the phase III Sympatico study.

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

Upadacitinib induces CD remission in patients with prior surgery

28 Dec 2023 by

Treatment with upadacitinib (UPA) delivers clinical benefits to patients with prior Crohn’s disease (CD)-related surgeries, according to a study presented at AIBD 2023. Moreover, a maintenance dose of 30 mg once a day (QD) demonstrates greater efficacy.

Upadacitinib induces CD remission in patients with prior surgery

28 Dec 2023

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023 by

The novel, investigational anti-tissue factor pathway inhibitor marstacimab outdid factor replacement therapy (FRT) in reducing bleeds in patients with severe haemophilia A (HA) or moderately severe to severe haemophilia B (HB) without inhibitors beyond 12 months in the phase III BASIS trial.

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Fluvoxamine of little benefit in mild-to-moderate COVID-19

Fluvoxamine of little benefit in mild-to-moderate COVID-19

Retinoblastoma treatment carries increased risk of neutropenia

Retinoblastoma treatment carries increased risk of neutropenia

Statins protect against blood clots in people taking hormone therapy

Statins protect against blood clots in people taking hormone therapy

Is premedication with pronase advisable to patients undergoing endoscopy?

Is premedication with pronase advisable to patients undergoing endoscopy?

Telitacicept shows promise in systemic lupus erythematosus

Telitacicept shows promise in systemic lupus erythematosus

Brolucizumab noninferior to aflibercept for diabetic macular edema

Brolucizumab noninferior to aflibercept for diabetic macular edema

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Upadacitinib induces CD remission in patients with prior surgery

Upadacitinib induces CD remission in patients with prior surgery

Marstacimab trumps FRT for severe haemophilia without inhibitors

Marstacimab trumps FRT for severe haemophilia without inhibitors